Omeros Corporation - Product Pipeline Review - 2016

  • ID: 3837880
  • Company Profile
  • 115 pages
  • Global Markets Direct
  • Omeros Corporation
1 of 4
Omeros Corporation - Product Pipeline Review - 2016

Summary

‘Omeros Corporation - Product Pipeline Review - 2016’, provides an overview of the Omeros Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Omeros Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Omeros Corporation
- The report provides overview of Omeros Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Omeros Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Omeros Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Omeros Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Omeros Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Omeros Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Omeros Corporation Snapshot

Omeros Corporation Overview

Key Information

Key Facts

Omeros Corporation - Research and Development Overview

Key Therapeutic Areas

Omeros Corporation - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Omeros Corporation - Pipeline Products Glance

Omeros Corporation - Late Stage Pipeline Products

Omeros Corporation - Clinical Stage Pipeline Products

Omeros Corporation - Early Stage Pipeline Products

Omeros Corporation - Drug Profiles

OMS-721

OMS-405

OMS-824

Monoclonal Antibodies for Oncology, Metabolic, Cardiovascular and Musculoskeletal Disorders

Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications

OMS-527

OMS-616

OMS-906

Small Molecule to Agonize GPR52 for Schizophrenia

Small Molecule to Agonize PTH-1R for Osteoporosis

Small Molecule to Antagonize GPR101 for Appetite Disorders

Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders

Small Molecule to Antagonize GPR139 for Motor Disorders

Small Molecule to Antagonize GPR15 for Rheumatoid Arthritis and HIV-Mediated Enteropathy

Small Molecule to Antagonize GPR161 for Oncology, Ophthalmology and Central Nervous System Disorders

Small Molecule to Antagonize GPR17 for Central Nervous System Disorders

Small Molecule to Antagonize GPR173 for Obesity and Schizophrenia

Small Molecule to Antagonize GPR182 for Pancreatic Cancer

Small Molecule to Antagonize GPR19 for Metastatic Melanoma and Lung Cancer

Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia

Small Molecule to Antagonize GPR27 for Obesity, Diabetes and Schizophrenia

Small Molecule to Antagonize GPR31 for Anxiety Disorders

Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes

Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia

Small Molecule to Antagonize GPR85 for Obesity and Schizophrenia

Small Molecule to Antagonize GPR87 for Oncology

Small Molecule to Antagonize NMUR2 for Pain

Small Molecule to Antagonize OPN4 for Circadian Rhythm Irregularities and Sleep Disorders

Small Molecule to Antagonize P2Y8 for Acute Lymphoblastic Leukemia and Lymphoma

Small Molecule to Inhibit CCRL2 for Rheumatoid Arthritis and Immune Disorders

Small Molecule to Target GPR132 for Cardiovascular Diseases

Small Molecule to Target GPR135

Small Molecule to Target GPR141 for Respiratory and Immune Disorders

Small Molecule to Target GPR150 for Ovarian Cancer

Small Molecule to Target GPR151 for CNS Diseases

Small Molecule to Target GPR153 for Schizophrenia

Small Molecule to Target GPR162 for Neuropsychiatric Disorders

Small Molecule to Target GPR171 for Eating and Hematological Disorders

Small Molecule to Target GPR174 for Immunology, Neurology and Oncology

Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections

Small Molecule to Target GPR21 for Obesity and Diabetes

Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis

Small Molecule to Target GPR25 for Arterial Stiffness

Small Molecule to Target GPR32 for Acute Inflammation

Small Molecule to Target GPR37 for Parkinson's Disease

Small Molecule to Target GPR37L1 for Hypertension and Cardiac Hypertrophy

Small Molecule to Target GPR45

Small Molecule to Target GPR50 for CNS and Metabolic Disorders

Small Molecule to Target GPR63 for Autism

Small Molecule to Target GPR65 for Oncology and Inflammatory Disorders

Small Molecule to Target GPR80 for Hepatocellular Carcinoma

Small Molecule to Target GPR82 for Appetite Disorders and Body Weight

Small Molecule to Target GPR83 for CNS and Immunological Disorders

Small Molecule to Target LGR4 for Oncology and Osteoporosis

Small Molecule to Target LGR5 for Esophageal Adenocarcinoma

Small Molecule to Target LGR6 for Dermatology

Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer

Small Molecule to Target MRGE for Pain

Small Molecule to Target MRGF

Small Molecule to Target OGR1 for Oncology, Bone Diseases, Asthma and Osteoporosis

Small Molecule to Target OPN5

Small Molecules to Agonize GPR61 for Eating Disorder

Small Molecules to Target GPR146 for Metabolic Disorders

Omeros Corporation - Pipeline Analysis

Omeros Corporation - Pipeline Products by Target

Omeros Corporation - Pipeline Products by Route of Administration

Omeros Corporation - Pipeline Products by Molecule Type

Omeros Corporation - Pipeline Products by Mechanism of Action

Omeros Corporation - Recent Pipeline Updates

Omeros Corporation - Dormant Projects

Omeros Corporation - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Omeros Corporation - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Omeros Corporation, Key Information

Omeros Corporation, Key Facts

Omeros Corporation - Pipeline by Indication, 2016

Omeros Corporation - Pipeline by Stage of Development, 2016

Omeros Corporation - Monotherapy Products in Pipeline, 2016

Omeros Corporation - Phase III, 2016

Omeros Corporation - Phase II, 2016

Omeros Corporation - Preclinical, 2016

Omeros Corporation - Discovery, 2016

Omeros Corporation - Pipeline by Target, 2016

Omeros Corporation - Pipeline by Route of Administration, 2016

Omeros Corporation - Pipeline by Molecule Type, 2016

Omeros Corporation - Pipeline Products by Mechanism of Action, 2016

Omeros Corporation - Recent Pipeline Updates, 2016

Omeros Corporation - Dormant Developmental Projects,2016

Omeros Corporation - Discontinued Pipeline Products, 2016

Omeros Corporation, Subsidiaries 113List of Figures

Omeros Corporation - Pipeline by Top 10 Indication, 2016

Omeros Corporation - Pipeline by Stage of Development, 2016

Omeros Corporation - Monotherapy Products in Pipeline, 2016

Omeros Corporation - Pipeline by Top 10 Target, 2016

Omeros Corporation - Pipeline by Route of Administration, 2016

Omeros Corporation - Pipeline by Molecule Type, 2016

Omeros Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll